OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
企業コードOABIW
会社名OmniAb Inc
上場日Oct 09, 2020
最高経営責任者「CEO」Mr. Matthew William (Matt) Foehr
従業員数- -
証券種類Company Warrant
決算期末- -
本社所在地5980 Horton Street
都市EMERYVILLE
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号94608
電話番号15102507800
ウェブサイトhttps://www.omniab.com/
企業コードOABIW
上場日Oct 09, 2020
最高経営責任者「CEO」Mr. Matthew William (Matt) Foehr
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし